For decades, drug development has been dominated by small molecules (targeting proteins) and antibodies (blocking protein function). Yet approximately 85 percent of disease-causing proteins were considered “undruggable” – until RNA interference (RNAi) emerged. Small interfering RNA (siRNA) therapeutics work upstream, silencing specific messenger RNA (mRNA) before proteins are even produced. This fundamentally different mechanism enables treatment of genetic disorders, certain cancers, viral infections, and neurodegenerative diseases previously beyond reach. For pharmaceutical executives, R&D directors, and investors, the core demands are: understanding siRNA’s gene silencing potential beyond rare diseases, navigating delivery system innovations (GalNAc conjugation, lipid nanoparticles), and capitalizing on the shift from intravenous to patient-friendly subcutaneous injection. This analysis provides application-specific insights across nervous system therapy, endocrine and metabolic disorders, and oncology, based exclusively on QYResearch verified market data, corporate annual reports (2025–2026), and regulatory publications.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “siRNA Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global siRNA Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4771743/sirna-drugs
Market Size and Recent Growth Trajectory (2024–2031) in USD
The global market for siRNA Drugs was estimated to be worth USD 2,443 million in 2024 and is forecast to reach a readjusted size of USD 16,238 million by 2031, growing at a CAGR of 28.9 percent during the forecast period 2025-2031.
The CEO takeaway: A 28.9 percent CAGR over seven years – from USD 2.4 billion to USD 16.2 billion – reflects siRNA’s transition from rare disease orphan drugs (first approval in 2018) to mainstream therapeutics for chronic diseases affecting millions. This growth trajectory positions siRNA as the third major drug modality after small molecules and monoclonal antibodies.
Regional dynamics: The United States is the largest consumption region, accounting for approximately 57 percent of the global market, followed by Europe. This concentration reflects earlier regulatory approvals (FDA) and established reimbursement pathways for novel biologics.
Product Definition – Mechanism and Core Advantages
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA, typically 20–24 (normally 21) base pairs in length, operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression.
siRNA-based therapeutics have gained significant attention due to their potential to target specific genes involved in cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses design, development, testing, and regulatory approval.
Key advantages over traditional modalities:
Any gene targetable: No requirement for “druggable” protein pockets – siRNA can silence any gene with a known sequence
Long duration of action: Chemical modifications extend half-life to weeks; Leqvio (Novartis) requires subcutaneous injection only twice annually
Predictable design: Sequence rules enable rapid development once target gene is validated
Market Segmentation by Type and Application
Segment by Type (Route of Administration)
Type Market Share (2024) Characteristics Key Products
Subcutaneous Injection 77% Patient-administered, convenient for chronic disease, requires chemical stabilization (GalNAc conjugation) Leqvio (hypercholesterolemia), Oxlumo (hyperoxaluria)
Intravenous Injection 23% Clinic/hospital administration, higher doses, earlier technology (LNP delivery) Onpattro (hATTR amyloidosis), Givlaari (acute hepatic porphyria)
Subcutaneous injection dominates due to patient preference and the success of GalNAc conjugation technology, which enables liver-targeted delivery with infrequent dosing.
Segment by Application
Nervous System Therapy (largest segment, approximately 52 percent share): Includes neurodegenerative diseases (Alzheimer’s, Parkinson’s, Huntington’s), neuropathic pain, and CNS disorders. Growth driven by delivery breakthroughs enabling blood-brain barrier penetration. Denali’s RVT-1201 (targeting NLRP3 for Parkinson’s) represents the frontier.
Endocrine and Metabolic Therapy (fastest growing, projected 30-32 percent CAGR): Hypercholesterolemia (Leqvio), acute intermittent porphyria (Givlaari), primary hyperoxaluria (Oxlumo), and diabetes. Cardiovascular indications alone represent a multi-billion dollar opportunity.
Others (oncology, antiviral, genetic disorders): Includes liver cancers (Arrowhead’s ARO-HIF2), hepatitis B (Vir Biotechnology), and rare genetic diseases (multiple Alnylam programs).
Key Industry Characteristics – Six Pillars of siRNA Market Growth
Characteristic One: Technological Breakthroughs – From Laboratory to Clinic
Delivery system innovation – The critical enabler. Early siRNA drugs failed not from lack of potency but from inability to reach target tissues without degradation. Two breakthroughs solved this:
Lipid nanoparticle (LNP) technology optimization: through ionizable lipid component improvement and polyethylene glycol (PEG) modification, LNP achieves liver-targeted delivery (Alnylam’s Onpattro, 2018, first FDA-approved siRNA) or crosses the blood-brain barrier (Denali’s RVT-1201). LNP remains the standard for intravenous administration.
GalNAc conjugation technology (the game-changer): This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors on hepatocytes. GalNAc conjugates enable subcutaneous injection with infrequent dosing – Novartis’ Leqvio (inclisiran) is administered twice annually for LDL cholesterol lowering. By 2025, GalNAc conjugates represented over 80 percent of new siRNA clinical candidates.
Chemical modification improves stability and reduces immunogenicity: Through 2′-O-methyl modification, phosphorothioate backbone, and other technologies, siRNA half-life extends to several weeks, reducing immunogenicity and off-target effects.
Exclusive analyst observation – AI-assisted sequence design (Sirnaomics, others) combined with bioinformatics screening improves siRNA specificity, significantly improving clinical safety and reducing development attrition.
Characteristic Two: Indication Expansion – From Rare Diseases to Common Diseases
Breakthrough in chronic diseases: Approximately 1 billion cardiovascular disease patients globally represent enormous market potential for hypercholesterolemia treatment. Leqvio (Novartis) achieved blockbuster status (over USD 1 billion annual sales) within three years of launch.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (Arrowhead’s ARO-HIF2 for renal cancer) shows synergistic effects, pushing tumor immunotherapy into the gene regulation era. Eighteen siRNA oncology candidates were in clinical trials as of Q1 2026.
Personalized medicine rise: siRNA therapy based on genotyping (Alzheimer’s disease candidates targeting APOE4 mutation carriers) meets precision treatment needs, supporting premium pricing and higher patient willingness to pay.
Characteristic Three: Policy Support – Regulatory Framework Improvement
US FDA accelerated approval: Onpattro (2018) approved as first siRNA drug – regulatory green light established. Subsequently, Givlaari (2019), Oxlumo (2020), Leqvio (2020), and Amvuttra (2022) followed.
EMA adaptive pathways: Allow conditional approval based on surrogate endpoints (biomarker changes), shortening R&D cycles by 12-18 months.
China policy dividends: The 14th Five-Year Plan for Pharmaceutical Industry Development explicitly supports nucleic acid drugs and novel delivery systems. CDE (China drug regulator) implements fast approval for innovative siRNA drugs, with Sirnaomics’ STP705 (cutaneous squamous cell carcinoma) designated breakthrough therapy.
Characteristic Four: Capital Influx – Financing and Ecosystem Maturation
Investment and financing activity (2022-2025): Thirty-three financing events in small nucleic acid drugs in 2022 alone, raising nearly USD 1.5 billion. Sirnaomics’ IPO raised USD 100 million.
MNC (multinational corporation) strategic entry: Roche acquired Dicerna for USD 1.8 billion. Novartis and Alnylam reached USD 1.5 billion collaboration agreement. In 2025-2026, Novo Nordisk, Eli Lilly, and AstraZeneca all announced siRNA pipeline expansions.
CDMO service ecosystem matures: RiboBio, WuXi AppTec, and others provide one-stop services from sequence design to cGMP production, reducing R&D costs by over 50 percent.
Large-scale production breakthrough: Continuous flow synthesis technology increases siRNA annual production capacity from grams to kilograms. Cost per dose reduced to less than USD 10 for certain high-volume candidates approaching generic competition.
Characteristic Five: Competitive Landscape – From Technical to Ecological Barriers
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme (Sanofi), Arrowhead Pharmaceuticals, Silence Therapeutics, Sylentis, Avidity Biosciences, and Sirnaomics.
Exclusive analyst observation – Patent protection creates monopoly positions:
Delivery system core patents: Alnylam owns key technology patent clusters for LNP and GalNAc conjugation, creating a technological monopoly through 2035-2038. Competitors must develop non-infringing alternative chemistries (e.g., Avidity’s antibody-siRNA conjugates, Arrowhead’s TRiM™ platform).
Chemical modification patent network: Ionis Pharmaceuticals’ 2′-MOE modification and Sirnaomics’ proprietary GalNAc-siRNA coupling technology build patent moats.
Estimated 2024 market share by revenue:
Alnylam (including partnered/sublicensed products): 50-55 percent (multiple approved products, deepest pipeline)
Novartis (Leqvio exclusively, manufacturing/distribution): 25-30 percent
Sanofi/Genzyme (rare disease portfolio): 10-15 percent
Novo Nordisk, Arrowhead, Sirnaomics, others: 5-10 percent
Cross-border collaboration accelerating: Pharmaceutical-biotechnology alliances (AstraZeneca-Silence Therapeutics for cardiovascular siRNA) share R&D risks and returns. Academic-industry partnerships (Harvard University-Moderna RNA editing technology) promote translational research.
Characteristic Six: Challenges and Future Directions
Breakthrough in tissue penetration beyond liver. Current GalNAc and LNP technologies deliver primarily to liver. Expanding to lung (via inhaled formulations, cell-penetrating peptides), brain (exosome delivery, focused ultrasound opening blood-brain barrier), and muscle represents the next frontier. Fourteen companies are developing non-liver delivery platforms in 2026.
Long-term safety assessment. Establish real-time quantitative PCR to monitor off-target effects; combine single-cell RNA sequencing with AI-driven sequence optimization.
Balance cost and accessibility for global markets. Tiered pricing strategy in low- and middle-income countries; consider patent pool models (Medicines Patent Pool, MPP) for neglected diseases.
User Case – The Cholesterol Lowering Blockbuster
Leqvio (inclisiran, Novartis) provides the most compelling market validation. Approved in 2020 (FDA) and 2021 (EMA), Leqvio targets PCSK9 for LDL cholesterol reduction. Unlike monoclonal antibody PCSK9 inhibitors (Repatha, Praluent) requiring injections every 2-4 weeks, Leqvio requires subcutaneous administration twice annually after an initial loading dose.
Clinical results (Phase III ORION-9/10/11 pooled analysis): LDL reduction 50-55 percent sustained over 18 months with two injections. Adherence rates exceeding 95 percent (versus 50-60 percent for daily oral statins).
Commercial performance (2023-2025):
2023: USD 410 million (launch year)
2024: USD 870 million
2025: USD 1,350 million (blockbuster status)
2026 projected: USD 1,800-2,000 million
The CEO takeaway: A chronic disease indication (cardiovascular, 1 billion patients globally) with infrequent subcutaneous dosing created a multi-billion dollar siRNA blockbuster within three years of launch. This template is being replicated in metabolic (diabetes), neurologic (Alzheimer’s risk reduction), and respiratory diseases.
What This Means for Decision Makers
For pharmaceutical company R&D executives: Evaluate pipeline expansion into siRNA for targets where protein-based biologics have failed or are inconvenient. The “two-dose annually” paradigm (Leqvio) resets patient expectations for chronic disease management. Delivery technology access (GalNAc licensing, LNP, novel platforms) is the primary barrier – Alnylam’s patent estate dominates liver.
For investors: The siRNA drugs market (USD 2.44 billion in 2024, 28.9 percent CAGR to USD 16.24 billion by 2031) offers exposure to the third major drug modality. Alnylam is the safe leader (technology originator, deepest pipeline). Novartis has blockbuster commercial execution (Leqvio). Arrowhead, Sirnaomics, Silence, and Avidity offer higher-risk, higher-potential pure-play exposure.
For corporate development and licensing executives: The window for non-liver delivery platforms is closing – exclusive licenses for lung, CNS, and muscle siRNA delivery are being signed in 2025-2027. Act before liposomal, exosome, and CPP (cell-penetrating peptide) platform exclusivity locks.
Conclusion
The siRNA drugs market, valued at USD 2.44 billion in 2024 and projected to reach USD 16.24 billion by 2031 (28.9 percent CAGR), represents the third major therapeutic modality after small molecules and monoclonal antibodies. GalNAc conjugation technology enables subcutaneous injection with infrequent dosing (Leqvio demonstrates twice-annual administration). LNP delivery remains standard for intravenous rare disease therapies. Nervous system therapy currently dominates (52 percent share), but endocrine and metabolic applications are fastest growing (30-32 percent CAGR). Alnylam leads patent-protected delivery platforms; Novartis leads commercial execution. As delivery expands beyond liver to lung, brain, and muscle, siRNA will address increasingly common diseases beyond rare genetic conditions. Download the sample PDF to access full segmentation, delivery technology patent landscape, and clinical pipeline analysis.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
